What price concessions for gabapentin were announced in December 2022?
I don’t have enough context to identify which specific “price concessions” you mean. In December 2022, different parties could have announced concessions related to gabapentin, such as:
- pharmacy or payer rebates/discounts,
- contract pricing changes for wholesalers,
- manufacturer discount programs,
- or regulatory/settlement-related pricing adjustments.
If you tell me the country (US, UK, Canada, etc.) and the source (e.g., a payer plan, a manufacturer press release, a specific brand name, or a document you’re looking at), I can pinpoint the exact concessions and summarize the key terms.
Are you looking for a specific document or filing (US vs. elsewhere)?
“Price concessions” often appears in:
- US CMS drug-price reporting and contracting contexts (payer/plan pricing rather than retail shelf price),
- state Medicaid announcements or pharmacy benefit manager (PBM) contracts,
- UK NHS procurement or managed access documents,
- Canadian provincial drug plan pricing.
Share any of the following and I’ll match it to the right December 2022 item:
- brand name (e.g., Neurontin or a generic),
- manufacturer/labeler,
- jurisdiction,
- a link or excerpt,
- whether you mean retail price, net price, or reimbursed price under a program.
How to interpret “concessions” for gabapentin (so you get the right numbers)
In drug pricing, concessions usually aren’t the same as “the price at the pharmacy counter.” They can refer to:
- discounts off a list price,
- rebates tied to utilization,
- formulary placement incentives,
- performance-based agreements,
- or negotiated reimbursement rates.
If you confirm whether you need retail price, net price, or payer reimbursement, I’ll format the answer accordingly.
Quick clarifying question
Which location and source are you referring to for “December 2022 price concessions gabapentin”?